BlinkRx

BlinkRx is excited to partner with Scienture LLC to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension of losartan potassium. Every year, millions of patients require a liquid form of losartan — yet until now, no FDA-approved, ready-to-use oral suspension has been available. With more than 71 million losartan prescriptions written annually, Arbli™ introduces a meaningful new option for patients who need an alternative to tablets. Read the full announcement: https://lnkd.in/eP5Ejw2z

The pharmacy landscape is shifting faster than ever, and the decisions leaders make today will define how patients access care in the years ahead. Tomorrow, BlinkRx’s Jonathan Lanznar joins industry leaders at ACCESS: Trade & Channel Strategies in Philadelphia for a conversation on where pharmacy is headed next and what it will take to meet rising expectations from patients, providers, and manufacturers. The discussion brings together executives from independent pharmacies, big-box retailers, grocery chains, and emerging models to examine how digital innovation, workflow pressures, and new access models are reshaping the pharmacy experience. Pharmacy Stakeholder Deep Dive December 9 | 2:00 PM | Philadelphia Registration: https://lnkd.in/eVUP-BSX Moderated by Joe Cappello, Head of Channel Accounts, Incyte Corporation #Pharmacy #Healthcare #PrescriptionAccess

Interesting data points from Phathom Pharmaceuticals' impressive Q3 earnings results: Cash prescriptions for VOQUEZNA grew 38% quarter-over-quarter, reaching 77,000 fills. In April, the company enabled Medicare patients to access the medication through cash-pay via BlinkRx — a population that previously had no coverage pathway. The company noted that Q3's cash prescription growth "includes the impact" of turning on this Medicare access. Total Q3 prescription volume: 221,000 total fills 144,000 covered prescriptions (23% growth QoQ) 77,000 cash prescriptions (38% growth QoQ) The takeaway: When you create an access pathway for patients who fall outside traditional coverage, prescription fills follow. At BlinkRx, cash-pay is one lever in our comprehensive platform. We work across the full spectrum of access and affordability barriers to increase fill rates for pharma clients and get patients the medications they need. https://lnkd.in/ep9RVN_N Investing.com

News: The U.S. Food and Drug Administration has approved Bayer's Lynkuet for easing hot flashes in menopausal women. The drug is a non-hormonal treatment designed to relieve moderate-to-severe vasomotor symptoms associated with menopause. We're proud to share that Bayer has partnered with us, and eligible patients may pay as little as $25 a month for this important therapy. https://lnkd.in/gpmfjRhr

Luke is exactly right. In this video, he tells us, "In 2025, 1 out of 5 prescriptions were abandoned." This is because the prescription journey is broken at every touchpoint: rejected claims, PA abandonment, pharmacy stock-outs, surprise costs at refill. Patients face barriers that are invisible with traditional data, and by the time you identify the drop-off, they're already gone. We've proven that pharma partners can increase fills per patient by 41% when they can see and control the entire prescription journey.

Geoffrey Chaiken, our Co-Founder and CEO, will join other top biotech and pharma CEOs, R&D heads, investors, and Longwood Healthcare Leaders at the upcoming Boston CEO meeting, for two days of discussion on the most important issues facing healthcare today. October 27-28, 2025 Mandarin Oriental, Boston We look forward to connecting with fellow leaders on patient-centric development, commercial success strategies, and transforming patient access. https://hubs.ly/Q03LNLP90

The past 25 years brought CRM systems, omnichannel engagement, and Next Best Action. Yet the core go-to-market model still relies on a 25-year-old claims data innovation. Time to modernize. Manufacturers need a platform that integrates real-time data. At BlinkRx, we offer two game-changing innovations: • Real-Time Access: Data delivered in real-time, not monthly or quarterly lags • Contribution Margin Data: Individual prescription profitability, not just volume Our Real-Time Rx Graph is a dynamic system capable of grouping data at any level, offering unprecedented visibility and actionability across sales, marketing, market access, and patient services. This represents a fundamental transformation: • From volume optimization to margin optimization • From quarterly adjustments to continuous improvement • From reactive analysis to proactive intervention By making real-time data foundational to their go-to-market strategy, today's innovators can create the next blockbuster with modern tools. Learn how to modernize your commercial data infrastructure in our white paper, Data Boom 2.0: https://hubs.ly/Q03KB17j0 Is your organization ready for the data revolution? #Pharma #PLMP #RealTimeData #Innovation

Traditional targeting focuses on high-volume prescribers, but our Real-Time Rx Graph shows contribution margin varies dramatically across HCPs. One client's top 1,400 physicians represented 2x the contribution margin versus volume-based targeting after accounting for patient support, channel fees, and PBM rebates. Get the complete framework in our white paper, Data Boom 2.0: https://hubs.ly/Q03J-Dqh0 #BlinkRx #DirectToPatient #PharmaTech #RealTimeData #PharmaInnovation #DigitalHealth #HealthcareInnovation

Most pharma brands still target prescribers by volume. But volume ≠ value. We found that if you prioritize prescribers based on their contribution margin rather than volume, you can double your contribution margin. The traditional model assumes: High-volume prescribers = high-value targets More scripts = more margin Bigger practices = bigger opportunity The reality our Real-Time Rx Graph shows: • Contribution margin varies wildly across prescribers • Patient support, channel fees, and PBM rebates dramatically impact profitability • Small practices can deliver higher margins than large ones When we rebuilt one client's target HCP list using real-time contribution margin data, their top 1,400 physicians represented 2x the contribution margin versus legacy volume-based methodologies. It's time to rethink how we define commercial success. Get the complete framework for transitioning from volume to margin-based targeting, including detailed case studies and implementation strategies, in our white paper Data Boom 2.0: The Power of Real-Time Data: https://lnkd.in/eehBB3Q5 If you want to double brand value, the easiest way is to target based on contribution margin instead of volume. #Pharma #CommercialStrategy #ROI #DataDriven

In a market this competitive, speed compounds. Acting on last quarter’s data is not enough. The leaders of tomorrow will act on today’s — and they’ll pull further ahead with every decision. Learn more: https://hubs.ly/Q03HySjT0 #Pharma #RealTimeData #Speed #CompetitiveAdvantage